GlassScriptPhysician profile
Mary Patterson
NPI 1295775310
$4,964.09
in general payments reported to CMS, 2019-2025
22 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,319 · 2023: $1,524 · 2024: $1,720 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,645.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,848.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $772.98 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $716.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $247.74 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.24 | 2022-2024 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $185.64 | 2023-2024 | Belsomra, Steglatro, Capvaxive |
| Abbvie INC. | $175.50 | 2022-2023 | |
| Pfizer INC. | $145.09 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.50 | 2022-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $103.57 | 2022 | |
| Glaxosmithkline, LLC. | $59.60 | 2022-2025 | Trelegy Ellipta |
| Abbott Laboratories | $55.13 | 2023-2025 | Proclaim |
| Exact Sciences Corporation | $46.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hydrofera LLC | $46.74 | 2024 | Hydrofera Blue |
| Sanofi-Aventis U.S. LLC | $40.39 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.37 | 2022 | |
| Idorsia Pharmaceuticals US INC | $39.12 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $36.75 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2022 | |
| Abiomed | $23.57 | 2024 | Impella |
| Xeris Pharmaceuticals, INC. | $23.10 | 2022 | |
| Shield Therapeutics INC | $15.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.